Schonfeld Strategic Advisors LLC Sells 272,368 Shares of Rezolute, Inc. (NASDAQ:RZLT)

Schonfeld Strategic Advisors LLC decreased its holdings in Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 79.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 71,932 shares of the company's stock after selling 272,368 shares during the period. Schonfeld Strategic Advisors LLC owned 0.12% of Rezolute worth $352,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. JPMorgan Chase & Co. purchased a new position in Rezolute in the 3rd quarter valued at approximately $42,000. Charles Schwab Investment Management Inc. increased its position in shares of Rezolute by 65.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock valued at $112,000 after buying an additional 9,000 shares during the period. Alpine Global Management LLC purchased a new stake in shares of Rezolute in the fourth quarter worth about $54,000. American Century Companies Inc. boosted its position in shares of Rezolute by 62.1% in the fourth quarter. American Century Companies Inc. now owns 64,591 shares of the company's stock valued at $316,000 after acquiring an additional 24,742 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Rezolute by 5.2% in the fourth quarter. Geode Capital Management LLC now owns 517,014 shares of the company's stock valued at $2,535,000 after acquiring an additional 25,413 shares during the period. Institutional investors own 82.97% of the company's stock.

Rezolute Stock Down 4.9%

Shares of Rezolute stock traded down $0.18 during trading on Wednesday, reaching $3.49. The company's stock had a trading volume of 792,856 shares, compared to its average volume of 620,276. Rezolute, Inc. has a 52-week low of $2.22 and a 52-week high of $6.19. The firm's 50-day moving average is $3.24 and its two-hundred day moving average is $4.34. The company has a market cap of $211.27 million, a price-to-earnings ratio of -2.86 and a beta of 1.01.

Rezolute (NASDAQ:RZLT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.05). On average, equities research analysts anticipate that Rezolute, Inc. will post -0.93 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Craig Hallum raised shares of Rezolute to a "strong-buy" rating in a report on Tuesday, February 4th. Wedbush restated an "outperform" rating and set a $12.00 target price on shares of Rezolute in a research report on Wednesday. JMP Securities raised their price target on Rezolute from $8.00 to $9.00 and gave the company a "market outperform" rating in a report on Thursday, February 13th. HC Wainwright reissued a "buy" rating and set a $14.00 price objective on shares of Rezolute in a report on Monday, April 28th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Rezolute in a research note on Monday, February 10th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $12.14.

Insider Buying and Selling

In other news, CEO Nevan C. Elam bought 12,302 shares of the business's stock in a transaction dated Thursday, March 27th. The shares were purchased at an average price of $2.85 per share, for a total transaction of $35,060.70. Following the completion of the acquisition, the chief executive officer now owns 224,119 shares of the company's stock, valued at approximately $638,739.15. This trade represents a 5.81% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Wladimir Hogenhuis bought 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was purchased at an average cost of $4.70 per share, for a total transaction of $47,000.00. Following the completion of the purchase, the director now owns 77,267 shares of the company's stock, valued at $363,154.90. This trade represents a 14.87% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 39,060 shares of company stock worth $130,694 in the last ninety days. 18.39% of the stock is owned by insiders.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.